Octahedral ruthenium (II) polypyridyl complexes as antimicrobial agents against mycobacterium | Zendy

Guojian Liao | Zendy; Zhengyuan Ye | Zendy; Yunlu Liu | Zendy; Bin Fu | Zendy; Chen Fu | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Octahedral ruthenium (II) polypyridyl complexes as antimicrobial agents against mycobacterium

Author(s) -

Guojian Liao,

Zhengyuan Ye,

Yunlu Liu,

Bin Fu,

Chen Fu

Publication year - 2017

Publication title -

peerj

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.927

H-Index - 70

ISSN - 2167-8359

DOI - 10.7717/peerj.3252

Subject(s) - ruthenium , mycobacterium smegmatis , cytotoxicity , octahedron , antimicrobial , chemistry , antibacterial activity , broth microdilution , mycobacterium tuberculosis , minimum inhibitory concentration , stereochemistry , minimum bactericidal concentration , medicinal chemistry , microbiology and biotechnology , tuberculosis , biology , bacteria , biochemistry , medicine , in vitro , organic chemistry , catalysis , pathology , crystal structure , genetics

Tuberculosis is one of the world’s deadliest infectious disease with 1.5 millions deaths annually. It is imperative to discover novel compounds with potent activity against M. tuberculosis . In this study, susceptibilities of M. smegmatis to the octahedral ruthenium(II) polypyridyl complexes, 1 {[(bpy) 3 Ru] (PF 6 ) 2 (bpy = 2,2′-bipyridine)}, 2 {[(phen) 2 Ru(dppz)](PF 6 ) 2 (phen = 1,10-phenanthroline, dppz = dipyridophenazine)} and 3 {[(phen) 3 Ru](PF 6 ) 2 } were measured by broth microdilution and reported as the MIC values. Toxicities of complex 3 to LO2 and hepG2 cell lines were also measured. Complex 2 inhibited the growth of M. smegmatis with MIC value of 2 µg/mL, while complex 3 was bactericidal with MIC value of 26 µg/mL. Furthermore, the bactericidal activity of complex 3 was dependent on reactive oxygen species production. Complex 3 showed no cytotoxicity against LO2 and hepG2 cell lines at concentration as high as 64 µg/mL, paving the way for further optimization and development as a novel antibacterial agent for the treatment of M. tuberculosis infection.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research